Results 41 to 50 of about 169,996 (318)
Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication. [PDF]
PLoS ONE, 2016 OBJECTIVES:In 2009, the FDA issued a warning that omeprazole--a proton pump inhibitor (PPI)--reduces the antithrombotic effect of clopidogrel by almost half when taken concomitantly.
Annie Guérin +6 more
doaj +1 more source
Aspirin and Clopidogrel Resistance [PDF]
Mayo Clinic Proceedings, 2006 Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as determined by standard platelet assays.
Richard A. Lange +4 more
openaire +3 more sources
The synthesis of clopidogrel [PDF]
IOP Conference Series: Materials Science and Engineering, 2017 Cardiac and cerebrovascular disease is a common disease. It is well recognized that antiplatelet agent is effective in the prevention and treatment of thrombosis. Clopidogrel is one of thieno pyridine derivatives, which can inhibit ADP-induced platelet aggregation.
Yuanjun Huang, Qingxin Zhu
openaire +1 more source
Assessing Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Incidence of Major Adverse Cardiovascular Events: A Retrospective Cohort Study. [PDF]
Pharmacoepidemiol Drug SafABSTRACT Purpose Clopidogrel, an antiplatelet agent used to prevent ischemic events, may interact with proton pump inhibitors (PPIs), especially omeprazole and esomeprazole, and reduce its effectiveness. The evidence surrounding this interaction remains controversial.
Algabbani AM, Almohareb SN, Alrwisan AA.
europepmc +2 more sources
Clopidogrel for the Hot Patient [PDF]
Circulation: Cardiovascular Interventions, 2009 Inflammation plays a critical role in the initiation, progression, and clinical complications of atherosclerosis.1 Experimental evidence indicates that lesion formation is dependent on heterotypic interactions among immune cells, endothelial cells, and platelets.
Daniel I. Simon, Matthew L. Bilodeau
openaire +3 more sources
International Journal of Gerontology, 2018 Summary: Background: This study aims to measure platelet aggregation with thromboelastography (TEG) and observe low response to clopidogrel in patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy.
Lijia Zhao +3 more
doaj +1 more source
Brazilian Journal of Cardiovascular SurgeryIntroduction: Antiplatelet therapy after coronary artery bypass graft (CABG) has been used. Little is known about the predictors and efficacy of clopidogrel in this scenario. Objective: Identify predictors of clopidogrel following CABG.
Paulo Roberto L. Prates +9 more
doaj +1 more source
Swiss Medical Weekly, 2012 BACKGROUND: Patients who have acute coronary syndromes with or without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy of early clopidogrel administration (300 mg) (
Jean Christophe Stauffer +5 more
doaj +1 more source
Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal
Periodontology 2000, EarlyView., 2023 Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra +3 more
wiley +1 more source
JAMA Internal Medicine, 2020 Importance Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased ...
R. Turgeon +6 more
semanticscholar +1 more source